当前位置:首页 >财报库 > 报告详情

【原美源伯根】Cencora(COR)2026财年第一季度财报(10-Q)「NYSE」(英文版)(42页).pdf

上传人: 1****1 编号:1188403 2026-04-13 42页 454.26KB

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934FOR THE QUARTERLY PERIOD ENDED December 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EX

2、CHANGE ACT OF 1934FOR THE TRANSITION PERIOD FROM _ TO_Commission file number 1-16671 CENCORA,INC.(Exact name of registrant as specified in its charter)Delaware 23-3079390(State or other jurisdiction of(I.R.S.Employerincorporation or organization)Identification No.)1 West First AvenueConshohocken,PA

3、19428-1800(Address of principal executive offices)(Zip Code)(610)727-7000(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of exchange on which registeredCommon stock,par value$0.01 per shareCORNew Yor

4、k Stock Exchange(NYSE)2.875%Senior Notes due 2028COR28New York Stock Exchange(NYSE)3.625%Senior Notes due 2032COR32New York Stock Exchange(NYSE)Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 duri

5、ng the preceding 12 months(or for suchshorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No o Indicate by check mark whether the registrant has submitted electronically,every Interactive Data File required

6、 to be submitted and posted pursuant to Rule 405 of Regulation S-T during thepreceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes No o Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerate

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **公司概况**:Cencora, Inc.(前身为AmerisourceBergen)是一家在纽交所上市的大型医药分销商,业务涵盖美国及国际医疗解决方案。 2. **财务表现**:2025年Q4营收859.3亿美元,净利润5.60亿美元;同比2024年Q4营收814.9亿美元,净利润4.89亿美元。 3. **重大收购**:2025年1月以40.42亿美元现金收购眼科公司RCA 85%股权,并承担6.94亿美元股权单位等或有对价。 4. **债务与融资**:总债务79.22亿美元,新增364天期贷款30亿美元用于收购OneOncology;商业票据借款2.20亿美元。 5. **诉讼风险**: opioid相关诉讼计提负债43亿美元(含巴尔的摩案4240万美元),计划13年分期支付。 6. **资产减值**:因出售美国咨询业务,计提商誉减值1.66亿美元。
**Cencora财报亮点?** ** opioid诉讼进展?** **RCA收购影响?**
客服
商务合作
小程序
服务号
折叠